NICE Endorses Talazoparib Enzalutamide for Pros...

By HEOR Staff Writer

January 23, 2026

NICE Backs Talazoparib-Enzalutamide for Advanced Prostate Cancer The National Institute for Health and Care Excellence (NICE) has recommended talazoparib enzalutamide ...
Navigating Targeted Therapy Access: Innovations and Challenges in High-Cost T...
Ravulizumab aHUS Reimbursement Reassessment: Navigating New Evidence and Trea...
Global Drug Price Gaps Demand Better Drug Pricing Analysis
Aligning Market Access Strategies with the WHO’s Global Lung Health Resolution
MR-107A-02: Revolutionizing Non-Opioid Pain Management with Viatris’ Breakthr...
South Africa NHI Bill Court Ruling Calls for Scrutiny
Ivonescimab NMPA Approval Signals Breakthrough in Lung Cancer
Enhancing UK Clinical Trials Inclusivity: Opportunities and Innovations in Me...
Cholera Vaccination Campaign Amid Ongoing Outbreak
Promising Dual Immunotherapy for Anaplastic Thyroid Cancer
Advancing Newborn Screening for Sickle Cell Disease in Africa
Thyroid Eye Disease Therapy: Insights from Viridian Therapeutics’ THRIV...